RSS

Latest Issue of EPM

Latest EPM Issue

Experience. Precision for Radiopharma Logistics. Marken
Winning the race against time with precision for critical Radiopharma shipments.

European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturer - Nov/Dec 2024
The Nov/Dec 2024 issue of EPM Magazine explores the latest insights on regulations, manufacturing and testing & inspection, plus a cover story from Tower Cold Chain.
European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturer - Sept/Oct 2024
The Sept/Oct 2024 issue of EPM Magazine explores the latest insights on regulations, digital health and coatings plus a cover story from SHL Medical.
European Pharmaceutical Manufacturer - May/June 2024
The May/June 2024 issue of EPM Magazine explores the latest insights on cell & gene therapy, bioprocessing, packaging and manufacturing plus the opinion from AstraZeneca and a cover story from Fette.
European Pharmaceutical Manufacturer - March/April 2024
The March/April 2024 issue of EPM Magazine explores the latest clinical trials insights, a Q&A with Lonza, how automation and robotics are shaping the future, analysing advancing clinical trials manufacturing from pilot to production and more!
European Pharmaceutical Manufacturer - Jan/Feb 2024
The Jan/Feb 2024 issue of European Pharmaceutical Manufacturer explores the latest packaging trends, a Q&A with Lonza, Drug Delivery & Devices, Sustainability, plus Biopharma and Manufacturing insights alongside Element Materials Technologies.

Stevanato Group
A one-stop shop for even the most challenging Monoclonal Antibodies (mAbs)
The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
12 Mar 2025
08:00

Sorry, no results.

Experience. Precision for Radiopharma Logistics. Marken
Winning the race against time with precision for critical Radiopharma shipments.

Stevanato Group
A one-stop shop for even the most challenging Monoclonal Antibodies (mAbs)
The biologics market is expanding rapidly – with a compound annual growth rate of 15% predicted until 2027. But this new generation of drugs comes with unique challenges that require an innovative approach underpinned by extensive experience.
12 Mar 2025
08:00